Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25208894 | 1.00 | CA1 (0.59) | CA1CA2MAOBMAPTNPC1 | |
| SCHEMBL31233292 | 1.00 | CA1 (0.59) | CA1CA2MAOBMAPTNPC1 | |
| SCHEMBL30384395 | 1.00 | CA1 (0.59) | CA1CA2MAOBMAPTNPC1 | |
| SCHEMBL25216238 | 0.87 | MAPT (0.74) | MAOBMAPTNPC1RAB9AHDAC3 | |
| SCHEMBL25200446 | 0.87 | MAPT (0.74) | MAOBMAPTNPC1RAB9AHDAC3 | |
| SCHEMBL30382887 | 0.87 | MAPT (0.74) | MAOBMAPTNPC1RAB9AHDAC3 | |
| SCHEMBL30383968 | 0.87 | MAPT (0.74) | MAOBMAPTNPC1RAB9AHDAC3 | |
| SCHEMBL25208497 | 0.86 | MAPT (0.75) | MAOBMAPTNPC1RAB9AHDAC3 | |
| SCHEMBL25200405 | 0.86 | HDAC3 (0.59) | CA1CA2MAOBMAPTNPC1 | |
| SCHEMBL25195512 | 0.86 | HDAC3 (0.59) | CA1CA2MAOBMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | CA1 4078/4885CA2 2635/4885MAOB 1004/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | CA1 3374/4885CA2 2843/4885MAOB 2435/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | CA1 3374/4885CA2 2843/4885MAOB 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.